Cefaly — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Cefaly is a commercial-stage medical device company focused on providing a non-pharmacological treatment for migraine. Its flagship product, the CEFALY device, is a wearable that delivers external trigeminal nerve stimulation (e-TNS) and is cleared for both acute pain relief and preventive reduction of migraine frequency. The company has established direct-to-consumer and healthcare professional channels, supported by clinical data and physician testimonials. As a private company, it operates in the large and growing global migraine market, competing with pharmaceuticals and other neuromodulation devices.

MigraineNeurology

Technology Platform

External Trigeminal Nerve Stimulation (e-TNS) delivered via a wearable forehead device for neuromodulation to treat and prevent migraine.

Opportunities

The massive global migraine patient population (over 1 billion) with significant unmet need for tolerable, non-drug treatments presents a major opportunity.

The over-the-counter, direct-to-consumer model allows for broad access without the barrier of a prescription, and growing physician acceptance of neuromodulation supports market expansion.

Risk Factors

Intense competition from advanced pharmaceuticals (e.g., CGRP inhibitors) and other neuromodulation devices poses a significant market share risk.

The lack of widespread insurance reimbursement places the full cost on patients, potentially limiting adoption.

Commercial execution risks include scaling manufacturing to meet demand and effectively educating the market.

Competitive Landscape

Cefaly competes in the migraine treatment market against a wide range of pharmaceuticals (triptans, gepants, CGRP mAbs) and other neuromodulation devices such as electroCore's gammaCore (vagus nerve stimulator) and Theranica's Nerivio (remote electrical neuromodulation). Its key differentiators are its dual acute/preventive function, over-the-counter status, and specific focus on trigeminal nerve stimulation.

More companies in Neuroscience & CNS →More companies in Belgium →